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EVALUATING THE EXPRESSION OF UROKINASE 
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INTRODUCTION
Breast cancer is the leading cause of death for cancer in western 
world women. The deeper knowledge of its biological complexity, 
has led us to consider this disease as potentially systemical from the 
early stages of his debut, focusing the attention of researchers on 
understanding the metastatic mechanism. 
The metastasis of tumour cells involves the breaking of the basal 
membrane and extracellular matrix.
The urokinase (uPA) plays a central role in converting plasminogen 
into the fundamental effector plasmin, responsible of the 
proteolysis of the extracellular matrix and basement membranes. 
(1, 2); it has attracted the curiosity of many researchers who have 
highlighted its biological functions in many models of neoplasia 
(3). Its current clinical use mostly concerns its prognostic and  
predictive role in the field of breast malignancy. A further and 
interesting scientific frontier is the one relating to the possible use 
of urokinase and of the elements of its whole system as innovative 
and effective therapeutic targets to prevent the systemic spread of 
the disease.
In this study, we analyzed the concentration of uPA in malignant 
breast lesions, in benign breast lesions and in breast tissue free 
from disease.
MATERIALS AND METHODS
The analyzed samples are taken from a population of women 
relating to the program of breast screening Breast Care Unit of the 
University of Rome "La Sapienza", "Palazzo Baleani" (EO C06 - 
UOC Territorial Surgical Medicine for cancer prevention). The 
project was approved by the Ethics Committee of the Policlinico 
Umberto I, to which the breast unit belongs. The patients granted 
the informed consent to the participation in the study. From May 
2012 to September 2015, 71 women were enrolled: having 
followed the clinical instrumental exams for breast lump detection, 
they needed an investigation Mammotome, a biopsy using 
ultrasound or excisional biopsy. Moreover, as control group, 24 
not biopsied healthy women were enrolled, from whom just 
peripheral venous blood was withdrawn for the extraction of 
lymphocytes. Every enrolled woman was asked to permit  the 
study to have the availability of one or more simple of their tissues 
according to the list below:
1)  a small portion of the breast lesion biopsied;
2)  a small portion of healthy breast tissue adjacent to breast 
lesion;
3)  a sample of peripheral venous blood, for the extraction of 
leukocytes.
Once extracted, the breast tissue samples were immediately frozen 
and stored at -80 °C within two hours from the extraction; blood 
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Introduction: Our objectives is to show that the expression of uPA leukocyte could be considered, in the future,  as a marker of 
the expression of uPA in the malignant tissue and therefore a potential indicator of prognosis.
Methods: We examined the expression of uPa in leukocytes and tissues of three groups of women: with breast cancer;  with 
benign breast lesion and healthy women (control group). We used RT Real Time PCR assay. The expression of urokinase is 
significantly higher in malignant breast lumps compared to benign lesions. However, in women with carcinoma of the breast, 
malignant tissue expresses higher amounts of uPA than the healthy counterpart. There are no statistically significant differences in 
the expression of uPA, between tissues taken from women with benign lesions. The lymphocytes taken from healthy volunteers 
show a level of expression of uPA significantly lower than the other tested samples Lymphocytes extracted from cancer patients 
express higher amounts of uPA compared to lymphocytes belonging to women with benign breast lesions. The expression of uPA 
was compared with the clinical and biological parameters commonly used in clinical practice for the definition of the prognosis. 
The only exception found, concerns those tumors characterized by the simultaneous negativity for estrogen receptors, 
progesterone and HER2 (state of triple negative), in which the expression of uPA is very high.
Results and conclusions: Our data show that uPA expressed by leukocytes of each individual patient is the mirror image of the 
one expressed by malignant nodular uPA.
samples were stored in ice for a maximum of 6 hours and 
subsequently used for the extraction of leukocytes. Once extracted 
through a medium separation density gradient (Lymphocyte-H; 
methods), the leukocytes were frozen and stored at -80 ° C. The 
samples were divided into two groups: samples from patients with 
breast cancer and samples from patients with benign breast 
lesions. At the end of the enrollment  the collected samples were 
the following:
- 33 Malignant lesions,
- 33 Samples of healthy breast adjacent to carcinoma,
- 33 Leukocyte samples belonging to patients with breast 
cancer,
- 38 Benign breast lesions,
- 38 Samples of healthy breast tissue adjacent to the lesion 
benign breast
- 38 Leukocyte samples belonging to patients carriers of benign 
breast lesions.
- 24 Samples of leukocytes of healthy female volunteers free 
from nodular lesion of the breast at the breast screening; this 
last category of population represents the control group.
Characteristics of population. No woman had received any 
chemotherapy or radiotherapy before enrollment. Demographic 
characteristics of breast cancer patients are summarized in Table I; 
Table II summarizes the characteristics of the patients with benign 
breast lesion. Patients with malignant breast cancer have an 
average age of 58 years (32-81 years), 12 (36%) were 
premenopausal at the time of biopsy. The detected tumors were 
very invasive and most of them of the ductal type (93%), stage I 
(36%) with positive hormone receptor (72%), Her2 negative 
(72%) and medium low (85%) proliferation index (Ki67).
Extraction protocol of leukocytes from whole blood using 
Lymphocyte-H.
The extraction of leukocytes from whole blood was performed by 
Lymphocyte-H, following  the manufacturer's instructions. From 
each patient at least 3 ml peripheral venous blood were 
withdrawn, then collected in a tube with EDTA anticoagulant, 
preserved in ice, transported to the laboratory (within 6 hours of 
collection) and diluted with 3 ml of Phosphate Buffered Saline 
(PBS). The 6 ml of diluted blood, so obtained, were deposited over 
a quantity equal to 3 ml of Lymphocyte-H, using a 10-15 ml 
centrifuge tube. The test piece thus obtained was placed in 
centrifuge for 20 minutes at 800 g, at room temperature. At the 
end of the centrifuge, lymphocytes and monocytes are found at 
the interface blood- Lymphocyte-H and appear as a thin cloudy 
meniscus. With a Pasteur pipette cells deposited at the interface 
were removed and transferred to a new centrifuge tube for a final 
centrifugation at 800 g for 10 minutes with the purpose of 
eliminating the supernatant  and obtain a state of leukocytes 
easier to store at low temperatures.
Extraction protocol RNA-DNA and protein-expression 
analysis by RT-PCR.
The extraction of RNA-Protein-DNA was performed with the 
QIAGEN kit. After the homogenization, the sample was 
centrifuged several times in special tubes equipped with 
chromatographic column; adding buffers to different ionic 
strength, we removed progressively superfluous molecules, to 
separately extract RNA-DNA-Protein from leukocytes, then we 
read in a spectrophotometer the amount of DNA RNA present in 
the samples. 
Reverse transcription
With this step we obtained cDNA from RNA extracted previously.
The obtained cDNA was quantified  and using spectrophotometry
used as a template for RT-PCR.
PCR test on the housekeeping gene 18S
It was, therefore, performed a PCR test on the gene 18S. in 
practice, using a part of the cDNA back transcribed, we amplified a 
housekeeping gene, which by definition is expressed equally in all 
body cells. So, amplifying the 18S, starting from a same amount of 
cDNA for each sample, the same amount of cDNA amplified 18S 
should be obtained.
Real time PCR for quantification of uPA and 18S.
Finally, through real time PCR, we quantified the uPA gene. The 
amplification of the gene frees every cycle a measurable amount of 
fluorescence. The comparison of this fluorescence with that 
emitted during amplification of 18S allows an assessment of the 
amount of uPA expressed in the tested sample.
Evaluation of the state of methylation
For the study of the state of methylation on leukocytes we used 4 
leukocyte DNA samples previously extracted from patients with 
malignant breast disease and 4 leukocyte DNA samples from 
healthy women (control). For the study of the methylation status of 
the tissues we used four samples of  malignant breast tissue and 4 
samples of benign breast tissue (healthy breast tissue adjacent to 
the benign breast lesion) and from these we extracted the DNA 
using the Qiagen DNA KIT easy, following the protocol indicated 
by the KIT.PRODUCER
Statistical Analysis The Anova and Bonferroni post- test was 
used for the statistical evaluation of the data; Differences were 
considered significant at p <0.05. Each experiment was repeated 
at least three times. Histograms show the mean ± s.e.m. Asterisks 
affixed to the figures highlight the differences statistically 
significant; differences not highlighted by asterisks are not 
considered statistically significant.
RESULTS
Expression of urokinase in patients with breast cancer and 
in women with benign lesions.
The expression of urokinase is significantly higher in malignant 
breast lumps compared to benign lesions. (5.7 times vs. 3.8 times 
control; p <0.001) (fig1).
The tissues belonging to cancer patients express increased 
amounts of uPA compared to the tissues belonging to women 
with benign lesions. However, in women with carcinoma of the 
breast malignant tissue expresses higher amounts of uPA than the 
healthy counterpart does (5.7 times versus 4.7 times; p <0.01). 
There are no statistically significant differences in the expression of 
uPA, between tissues taken from women with benign lesions 
(comparing nodule and healthy breast). The lymphocytes taken 
from healthy volunteers show a level of expression of uPA 
significantly lower than the other tested samples (p <0.001).
Lymphocytes extracted from cancer patients express higher 
amounts of uPA compared to lymphocytes belonging to women 
with benign breast lesions (4.32 times versus 2.98 times; p <0.01). 
(figure 2).
The expression of uPA between nodule and lymphocytes is very 
similar, the average values  in this comparison are shown in figure 
3.
Expression of urokinase in relation with the clinical-
biological parameters.
The expression of uPA was compared with the clinical and 
biological parameters commonly used in clinical practice for the 
definition of the prognosis. These variables include: menopausal 
status, histological type, degree of cell proliferation (Ki67) the 
degree of expression of hormone (estrogen receptor and 
progesterone), HER2 status. In line with the behavior of uPA 
reported in the literature, the expression levels of uPA did not 
significantly differ in relation to the mentioned clinical-biological 
parameters. The only exception found, concerns those tumors 
characterized by the simultaneous negativity for estrogen 
receptors, progesterone and HER2 (state of triple negative), in 
which the expression of uPA is very high (11.9 times versus 5.5 
times; p <0.001).
DISCUSSION
The expression of urokinase has been associated with the 
development of various cancer diseases (4, 5, 6, 7, 8), including 
breast cancer. Despite its proteolytic function it has been 
consistently associated with the invasive capacity of malignant 
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tissues, many studies have shown the presence of urokinase 
antigen (or his messenger) even in benign breast lesions and in the 
glandular parenchyma free from disease (9, 10, 11). In this 
scientific study we compared the expression of uPA of mammary 
nodules (malignant and benign) to healthy tissues of the body.
We consider optimal the expression of urokinase quantified by RT-
PCR methodology, optimal because it permitted to determine the 
messenger of interest from very small amounts of tissue, such as 
those we could use for our research (12). In fact, initial tissue 
samples had been exclusively obtained by ultrasound-guided 
biopsy (Mammotome) or by surgical excision of small lesions 
(diameter less than 2 cm). Furthermore, the great sensitivity of the 
method is able to bring out even very small differences among the 
individual test samples (13).
To the physiological expression of uPA in leukocytes in healthy 
female women (ie,  free from nodular breast diseases to screening) 
we arbitrarily assigned a value of 1 (control) and expressed the 
uPA, measured in all other samples, as the number of times the 
value control was performed. We chose leukocytes extracted from 
peripheral venous blood as easy to be obtained with a simple blood 
test. The leukocytes of healthy volunteers show a weak expression 
of urokinase; this phenomenon, described in the literature, is due 
to the fact that uPA is an enzyme essential to support the migratory 
activity of leukocytes to sites of inflammation (14).
As shown in Figure I, malignant breast lesions have absolutely 
increased expression of uPA. Overexpression of uPA in malignant 
tissues compared with benign nodules emphasizes the role of 
proteases in the process of tumor invasion both local and remote. 
The different expression of urokinase between benign and 
ma l ignant  l e s ions ,  a l ready  repor ted  by  s tud ies  o f 
immunohistochemistry and in situ hybridization, is also clearly 
detectable by RT-PCR method. In order to study the expression of 
uPA in the complex system patient - cancer, we measured the 
expression of uPA not only in malignant tissue, but also in the 
following samples: the adjacent healthy breast; a sample of 
leukocytes extracted from peripheral blood.
The results obtained (Figure 1) show that, in spite of uPA is mainly 
expressed in malignant lesion, total uPA is overexpressed in all 
tissues extracted from cancer patients. Not a specific tissue, but the 
entire body overexpresses urokinase. When compared uPA 
nodular and uPA leukocyte in individually taken patients, with the 
exception of only few cases, uPA expressed by leukocytes of each 
individual patient is the mirror image of the one expressed by 
malignant nodular uPA. If this result (already obtained in a previous 
study) will be confirmed by larger sized studies, the expression of 
uPA leukocyte can be considered as a marker of the expression of 
uPA in the malignant tissue and therefore a potential indicator of 
prognosis.
Also leukocytes have been shown to be good markers of the 
methylation status of the organism: leukocytes obtained from 
healthy volunteers subjected to diet low in folate, show a reduced 
degree of global DNA methylation (15, 16).  The results from our 
study, highlighting the expression of uPA similar in various tissues 
taken from breast cancer patients, support the hypothesis that 
different forces that reduce the efficiency of the methylation 
machine, may alter the expression of those genes, as uPA, 
controlled by methylation. For this reason, after having confirmed 
the increased expression of uPA in tissue and lymphocytes of 
patients with breast disease, compared to healthy controls (Fig. 1-
2-3), we decided to study the methylation of  uPA gene  both in 
lymphocytes and in tissues through the technique of bisulfite. In 
our samples the uPA gene was found to be globally less metilated. 
The analysis showed that there is no significant difference of 
methylation in both lymphocytes and tissues, although in the latter 
a trend to increased methylation of CpG carcinomas (though not 
statistically significant) can be observed.
So we can say that the overexpression of uPA observed in our study 
is not regulated by methylation.
Finally, we wanted to compare the expression of urokinase with 
clinical and biological parameters, commonly used in clinical 
practice as prognostic factors (Figure 3). Urokinase is universally 
considered to be an independent prognostic factor in the course of 
breast cancer, second, for power, only to the axillary lymph node 
(17,18,19). In the samples examined, the values  of expression of 
uPA, in line with the data reported in the literature (20), are 
independent relative to the variables analyzed (hormone receptor 
status, HER2 status, value of Ki67, menopausal status). We report 
only one exception: a group of patients presents uPA mRNA levels 
significantly above the rest of the malignant tissues analyzed. 
These patients are connected by the concomitant negativity of 
estrogen hormone receptor, progesterone and HER2; this state is 
defined as "triple negative" and denotes a subgroup of patients 
with poor prognosis (21). These patients have a state of locally 
advanced disease; however, as reported in literature, uPA appears 
to be independent from the size of the primary lesion (T).
Although our findings need further confirmation on larger 
samples of patients, the correlation between overexpression of 
uPA and state of "triple negative" could explain the particular 
typical aggressiveness of these tumors.
In conclusion, the present scientific study confirms that uPA is 
overexpressed in malignant breast lesions compared with its 
expression in benign nodules, showing a specular expression of 
urokinase between malignant nodule and corresponding 
leukocytes, thus indicating the possibility of using urokinase 
leukocyte, as a marker of nodular uPA. In our opinion, the 
homogeneous expression of uPA found in all tissues analyzed 
(malignant lump, breast healthy tissues adjacent to the lesion, 
leukocytes), indicates not only a generic risk of developing cancer 
(as assumed by Piyathilake), but probably the tendency to cause a 
development of a more aggressive oncological diseases. High 
levels of uPA in the group of patients with ''triple negative''can 
justify the particularly inauspicious prognostic trend that 
characterizes these tumors and, at the same time, represent a 
therapeutic option for these patients, who do not have access to a 
targeted therapy for the deficiency of target receptors.
In addition, our study shows that the expression of uPA is not 
regulated by methylation, not having found statistically significant 
differences in the number of methylated CpG carcinomas and in 
controls. We detected a tendency in tissues, although not 
statistically significant, to a greater methylation in CpG : this data 
will be even further discussed  through other studies, involving an 
increased  number of samples analyzed and  of genes involved in 
this pathology, to finally clarify the mechanisms of the 
overexpression of uPA.
Table I: Characteristics of patients with malignant lesions 
(N = 33) 
characteristics patients




Stage of disease at the diagnosis











N1 mic 2 6,07
Stage hormone receptors
ER and/or PR positive 24 72,72
ER and PR negative 9 27,28
Valuation  HER-2 (IHC)*
+++ 9 27,28
negative 24 72,72
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Figure 1: Analysis of uPA by RT-PCR in malignant and benign 
breast lump and in healthy breast adjacent to the nodule.
Figure 2: Analysis of uPA by RT-PCR in leukocytes belonging 
to women with breast cancer and women with benign 
breast lesions; the control value is represented by uPA 
expressed in leukocytes of healthy, female volunteers.
Figure3: Averages of the values of the expression of uPA in 
samples of breast lump (benign or malignant) and the 
corresponding leukocytes.
REFERENCES
1) K. Bajou, JM. Lewalle, C.R. Martinez, C. Soria, H. Lu, Human breast 
adenocarcinoma cell lines promote angiogenesis by providing cells with uPA_PAI- 1 
and by enhancing their expression, 100 Int. J. Cancer (2002) 501-506.
2) D. Alfano, I. Iaccarino, M.P. Stoppelli, Urokinase signaling through its receptor 
protects against anoikis by increasing BCL-xL expression levels, J. Biol. Chem. 281 
(2006) 17758-67. 
3) Vallianou N.G.,Evangelopoulos A., Schizas N., Kazazis C. ,Potential anticancer 
properties and mechanisms of action of curcumin, Anticancer Res. 2015 
Feb;35(2):645-51.
4)  T.D. Kim, K.S. Song, G. Li, H. Choi, H.D. Park, K. Lim, B.D. Hwang, W.H. Yoon, 
Activity and expression of urokinase-type plasminogen activator and matrix 
metalloproteinases in human colorectal cancer, BMC Cancer 6 (2002) 211.
5)  S. Morita, A. Sato, H. Hayakawa, H. Ihara, T. Urano, Y. Takada, A. Takada, Cancer 
cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and 
inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting 
and in situ hybridation, Int. J. Cancer 78 (1998) 286-292.
6)  P.A. Usher, Expression of urokinase in prostate tissue, Int. J. Cancer 113 (2005) 
870-880.
7) C. Borgfeldt, S.R. Hansson, B. Gustavsson, A. Masback, B. Casslen, 
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated 
with increased expression of mRNA for urokinaseplasminogen activator (uPA), its 
receptor (uPAR), and its inhibitor (PAI1), Int. J. Cancer 92 (2001) 497-502.
8) C. Foca, E.K. Moses, M.A. Quinn, G.E. Rice, Differential mRNA expression of 
Urokinase-type plasminogen activator, plasminogen activator receptor and 
plasminogen activator inhibitor type-2 in normal human endometrial and 
endometrial carcinomas, Gynecol. Oncol. 79 (2000) 244-250.
9) V. Costantini, A. Sidoni, R. Deveglia, O.A. Cazzato, G. Bellezza, I. Ferri, E. 
Bucciarelli, G.G. Nenci, Combined overexpression of urokinase, urokinase 
receptor, and plasminogen activator inhibitor-1 is associated with breast cancer 
progression, Cancer 77(1996) 1079-1088.
10) E. Dublin, A. Hanby, N. K. Petel, R. Liebman and D. Barnes, Immunohistochemical 
expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic Expression has 
strong association with tumor pathology, Am. J. Pathol. 157 (2000) 1219-1227.
11) J.L. Fisher, C.L. Field, H. Zhou, T.L. Harris, M.A. Henderson, P.F.M. Chong, 
Urokinase plasminogen activator system gene expression is increased in human 
breast carcinoma and its bone metastases- A comparison of normal breast tissue, 
non-invasive and invasive carcinoma and osseous metastases, Breast Cancer Res. 
Treat. 61 (2000) 1-12.
12)  P.S. Bernard, C.T. Wittwer, Real-Time PCR technology for cancer diagnostics, Clin. 
Chem. 48 (2002) 1178-1185.
13) R. Castellò, A. Estellés, C. Vázquez, C. Falcò, F. España, S.M. Almenar, C. Fuster, J. 
Aznar, Quantitative Real-Time reverse transcription PCR assay for urokinase 
plasminogen activator, plasminogen activator inhibitor type 1, and tissue 
metalloproteinase inhibitor type 1gene expression in primary breast cancer, Clin. 
Chem. 48 (2002) 1288-1295.
14) E. Bianchi, E. Ferrero, F. Fazioli, F. Mangili, J. Wang, J.R. Bender, F. Blasi, R. Pardi, 
Integrin-dependent induction of functional urokinase receptors in primary T 
lymphocytes, J. Clin. Invest. 98 (1996) 1133-1141.
15)  R.A. Jacob, D.M. Gretz, P.C. Taylor, Moderate folate depletion increases plasma 
homocysteine and decreases lymphocyte DNA methylation in postmenopausal 
women, J. Nutr. 128 (1998) 1204-1212.
16) G.C. Rampersaud, G.P. Kauwell, A.D. Huytson, J.J. Cerda, L.B. Bailey, Genomic 
DNA methylation decreases in response to moderate folate depletion in elderly 
women, Am. J. Cli. Nutr. 72 (2000) 998-1003.
17) P. Leissner, T. Verjat, T. Bachelot, M. Paye, A. Krause, A. Puisieux, B. Mougin, 
Prognostic significance of urokinase plasminogen activator and plasminogen 
activator inhibior-1 mRNA expression in lymph node- and hormone receptor- 
positive breast cancer, BMC Cancer 6 (2006) 216.
18)  N. Harbeck, R.E. Kates, M.P. Look, M.E. Meijer-van Gelder, J.G.M. Klijn, A. Krüger, 
M. Kiechle, F. Jänicke, M. Schmitt, J.A. Foekens, Enhanced benefit from adjuvant 
chemotherapy in breast cancer patients classified high-risk according to urokinase-
type plasminogen activator (uPA) and plasminogen activator inhibitor type (n= 
3424), Cancer Res. 62 (2002) 4617-4622.
19) I. Zemzoum, R.E. Kates, J.S. Ross, P. Dettmar, M. Dutta, C. Henrichs, S. Yuedseven, 
H. Höfler, M. Kiechle, M Schmitt, N. Harbeck, Invasion factors uPA/PAI-1 and HER2 
status provide independent and complementary information on patient outcome 
in node-negative breast cancer, J. Clin. Oncol. 21 (2003) 1022  1028.
20)  J.C. Biermann, L. Holzscheiter, M Kotzsch, T. Luther, M. KiechleBahat, F.C.G.J. 
Sweep, P.N. Span, M. Schmitt, V. Magdolen, Quantitayive RT_PCR assay for the 
determination of urokinase-type plasminogen activator and plasminogen activator 
inhibitor type 1 mRNA in primary tumor of breast cancer patiens: comparision to 
antigen quantificatio by ELISA, Int. J. Mol. Med. 21 (2008) 251-259.
21)  G. Stockmans, K. Deraedt, H. Wildiers, P.Moerman, R. Paridaens, Triple negative 
breast cancer, 20 (2006) 614-620.








Other benign lesion 14 36,85
Dimensions 
<20mm 38 100
Triple-negative carcinoma 5 15,15




Abbreviationa: ER, estrogen receptors; PR   progesterone 
receptors, HER-2 Human epidermal growth factor 2; IHC, 
immunohistochemistry.
*stage HER-2  it was determined by  Hercept (Dako). No tumor 
was classified as ++ and than analyzed with dual-color 
fluorescent in situ hybridization (FISH).
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